Citation Impact
Citing Papers
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331
2000
Molecular mechanisms mediating metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α
2010
Validated assay for the simultaneous quantification of total vincristine and actinomycin‐D concentrations in human EDTA plasma and of vincristine concentrations in human plasma ultrafiltrate by high‐performance liquid chromatography coupled with tandem mass spectrometry
2009
Liposomes, a promising strategy for clinical application of platinum derivatives
2013
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy
2006
Separation methods for methotrexate, its structural analogues and metabolites
2001
Molecular mechanisms of drug resistance
2005
Ultrasound triggered release of cisplatin from liposomes in murine tumors
2009
Gold nanoparticles in delivery applications☆
2008 Standout
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Liposomal drug formulations in cancer therapy: 15 years along the road
2011
Triterpenoids as new promising anticancer drugs
2009 Standout
Nutrition and physical activity guidelines for cancer survivors
2012 Standout
A Phase I Study of SPI-077 (Stealth® Liposomal Cisplatin) Concurrent with Radiation Therapy for Locally Advanced Head and Neck Cancer
2002
Stimuli-responsive nanocarriers for drug delivery
2013 Standout
Transfer of Sulfur: From Simple to Diverse
2013 Standout
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release
2005
HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
2006 Standout
Nanocarriers for delivery of platinum anticancer drugs
2013
Nano based drug delivery systems: recent developments and future prospects
2018 Standout
Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients
2001
Controlled drug delivery vehicles for cancer treatment and their performance
2018 Standout
Liposome: classification, preparation, and applications
2013 Standout
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
2010 Standout
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
2016 Standout
Blinded by the Light: The Growing Complexity of p53
2009 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Chronic Health Conditions in Adult Survivors of Childhood Cancer
2006 Standout
New trends for metal complexes with anticancer activity
2008 Standout
Emerging Role of Liposomal Drug Carrier Systems in Cancer Chemotherapy
2003
Betulinic acid-induced apoptosis in leukemia cells
2004
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
2008 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents
2015 Standout
Platinum-based drugs: past, present and future
2016
Analysis of anticancer drugs: A review
2011 Standout
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Application of liposomal technologies for delivery of platinum analogs in oncology
2013
Long-term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk-based Health Care for Survivors
2004
Tumour-inhibiting platinum complexes—state of the art and future perspectives
2003
Cisplatin: The first metal based anticancer drug
2019 Standout
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Liposomes as nanomedical devices
2015 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation
2008
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma
2004
Gold nanoparticles in biomedical applications: recent advances and perspectives
2011 Standout
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
Liposomal encapsulated anti-cancer drugs
2005
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Complexation of Polyoxometalates with Cyclodextrins
2015 StandoutNobel
Therapeutic Nanoparticles for Drug Delivery in Cancer
2008 Standout
Enantioselective Total Syntheses of Plectosphaeroic Acids B and C
2013
Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study
2005
Marine natural products
2015 Standout
Methotrexate Conjugated to Gold Nanoparticles Inhibits Tumor Growth in a Syngeneic Lung Tumor Model
2007
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
2011 StandoutNobel
Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity
2005
Liposomal Formulations in Clinical Use: An Updated Review
2017 Standout
Mechanisms of Cisplatin Nephrotoxicity
2010 Standout
Cyclodextrin Capped Gold Nanoparticles as a Delivery Vehicle for a Prodrug of Cisplatin
2013
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
2009
Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts
2004
Enantioselective Total Synthesis of Plectosphaeroic Acid B
2013
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.
2005
Analysis of nanoparticle delivery to tumours
2016 Standout
Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer.
2010
Cellular uptake of nanoparticles: journey inside the cell
2017 Standout
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Hematological Problems in Pediatric Intensive Care
2013 Standout
Works of EJ Estlin being referenced
Clinical and cellular pharmacology in relation to solid tumours of childhood
2003
The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQTM in human leukaemia and colorectal carcinoma cell lines
1997
Optimizing antimetabolite‐based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia
2000
The cellular adaptations to hypoxia as novel therapeutic targets in childhood cancer
2008
The Clinical and Cellular Pharmacology Of Vincristine, Corticosteroids, l ‐Asparaginase, Anthracyclines and Cyclophosphamide In Relation To Childhood Acute Lymphoblastic Leukaemia
2000
A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin
2001
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
1999
Successful treatment of non-familial haemophagocytic lymphohistiocytosis with interferon and gammaglobulin.
1996